Clinical study in seven European countries compares the efficacy of two HIV drugs in people with advanced disease for the first time.
In a comprehensive clinical study led by Prof. Dr. Georg Behrens, senior physician at the Clinical Department of Rheumatology and Immunology at Hannover Medical School, researchers from 56 medical centers in Belgium, Germany, France, Great Britain, Ireland, Italy and Spain have looked at patients with advanced HIV disease and investigated which drugs work best for this group of patients. The results were published in The Lancet Infection Diseases.
About 450 newly diagnosed adults with advanced HIV disease were included in the study. Participants were randomly assigned to receive either integrase inhibitors or protease inhibitors as treatment. “Our study is the first large randomized controlled trial to compare the antiviral efficacy, recovery of the compromised immune system and possible side effects of first-line antiretroviral therapies specifically in people with advanced HIV disease,” emphasizes Professor Behrens.
Read the full news story here.
Source : Hannover Medical School
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.